​Effective May 29, 2023, AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey, and AmeriHealth Administrators will update their medical policy on ventricular assist devices (VADs).

The criteria section of this policy for percutaneous ventricular assist devices (pVADs) will be revised to reflect the updated labeling for the Impella^® RP System from the U.S. Food and Drug Administration (FDA) and in consideration of the Impella^® RP System final post-approval study (PAS) results.

For more information, view the policy notification for #11.02.16u: Ventricular Assist Devices (VADs), which was published on February 28, 2023.